CSIMarket
 
Vaxxinity Inc   (VAXX)
Other Ticker:  
 
 
Price: $0.7565 $0.05 7.764%
Day's High: $0.77 Week Perf: 2.73 %
Day's Low: $ 0.70 30 Day Perf: 7.7 %
Volume (M): 371 52 Wk High: $ 3.10
Volume (M$): $ 281 52 Wk Avg: $1.55
Open: $0.71 52 Wk Low: $0.56



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -53
 Cash Flow (TTM) (Millions $) -127
 Capital Exp. (TTM) (Millions $) 2

Vaxxinity Inc
Vaxxinity Inc is a biotechnology company that specializes in the development and production of vaccines for infectious diseases. The company was established in 2016, with its headquarters located in Boston, Massachusetts, USA. The company's main mission is to improve global health by preventing the spread of infectious diseases through the development and distribution of safe and effective vaccines.

Vaxxinity Inc's vaccine development platform combines in-house research with collaborations with academic institutions, government agencies, and industry partners. The company's approach is to develop vaccines that stimulate the body's immune system to fight infectious diseases. They believe that this approach is safer and more effective than traditional methods, such as attenuated or inactivated vaccines.

The company has an impressive portfolio of vaccines that are either in development or already approved for use. Some of the vaccines in their pipeline include vaccines for COVID-19, Zika virus, influenza, and rabies. Vaxxinity Inc's COVID-19 vaccine, VXN-19, is a protein-based vaccine that targets the spike protein of the SARS-CoV-2 virus. The vaccine is currently in phase II clinical trials and has shown promising results in preclinical studies.

Aside from vaccine development, Vaxxinity Inc is also involved in vaccine manufacturing and distribution. The company has partnerships with several contract manufacturing organizations (CMOs) to produce its vaccines in large quantities. They also have collaborations with government agencies, non-profit organizations, and other commercial partners to distribute their vaccines to those who need them the most, particularly in low- and middle-income countries.

Vaxxinity Inc is a relatively new company, but it has already gained recognition in the biotechnology industry for its innovative approach to vaccine development. The company has a team of experienced scientists, researchers, and business executives who are committed to achieving their mission of improving global health through the development of safe and effective vaccines.


   Company Address: 505 Odyssey Way Merritt Island 32953 FL
   Company Phone Number: 244-5739   Stock Exchange / Ticker: NASDAQ VAXX
   VAXX is expected to report next financial results on March 26, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Vaxxinity's Breakthrough Immunotherapy, UB-312, Shows Promise in Reducing Pathological Alpha-Synuclein in Parkinson's Patients

Published Thu, Mar 7 2024 3:32 PM UTC

Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD 2024Parkinson's disease is a debilitating neurodegenerative disorder that affects millions of people worldwide. Characterized by the gradual loss of dopamine-producing cells in the brain, Parkinson's leads to motor symptoms such as tremors, stiffness, and difficul...

Product Service News

Vaxxinity's Promising Cholesterol Vaccine Lowers LDL-C: Promising Preclinical Data Paves the Way to Uphold Cardiovascular Disease Management

Published Thu, Feb 15 2024 1:01 PM UTC

Vaxxinity's Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Promising Preclinical Data PublishedPreclinical data published in the Journal of Lipid Research has revealed that Vaxxinity Inc's cholesterol vaccine candidate, VXX-401, demonstrates immense potential in reducing LDL-C levels. These findings are instrumental in the ongoing battle against cardiovascular dise...

Vaxxinity Inc

Breakthrough COVID-19 Vaccine, VAXX, Achieves Remarkable Top-line Growth in Financial Time-frame Ending September 2023



Vaxxinity Inc, a pioneering U.S. pharmaceutical company, has recently reported its financial results for the third quarter ended September 30, 2023. While the figures may seem lackluster at first glance, a detailed analysis reveals some promising signs of progress and potential for the future.
Break-even Achievement and Revenue Stability:
In the financial time-frame ending September 30, 2023, Vaxxinity Inc reached a significant milestone, reporting a break-even of $0.00 per share. This marks a vast improvement compared to the prior year's break-even result and the previous reporting season's loss of $-0.11 per share.

Vaxxinity Inc

Vaxxinity Inc Shows Promise with Decreased Operating Deficit, Paving the Way for Future Growth



As the earnings season for the April to June 30, 2023 period unfolds, various companies have released their financial results. Among them, Vaxxinity Inc, a prominent player in the Major Pharmaceutical Preparations sector, has recently disclosed its operating deficit for the second quarter of 2023. While the current results indicate a decline in losses compared to the same quarter last year, it is crucial to analyze how these figures will impact the company's future prospects.
1. Decreased Operating Deficit:
Vaxxinity Inc registered an operating deficit of $-14.427 million in Q2 2023. Although this represents a loss for the quarter, it reveals a significant improvement since the previous year's result of $-17.252 million. This reduction in losses suggests that the company has made strides in managing its day-to-day operations effectively.

Vaxxinity Inc

Major Pharmaceutical Preparations Company, VAXX, Reports Significant Decrease in Performance for Q1 2023

The recent earnings season has seen a shakeup in the Major Pharmaceutical Preparations sector with VAXX announcing an operating deficit of $-18.808 million for the financial time-frame ending March 31 2023. This is certainly a matter of concern for the company and its stakeholders, but it is not the end of the road for the industry.
Amidst the challenges that VAXX and other companies in the sector are facing, there is still reason for optimism. The pharmaceutical industry is known for its ability to bounce back from setbacks and generate substantial revenue streams. Companies are constantly innovating and developing new drugs that can address prevailing health issues around the world.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com